Okupe Oluyemi, serving as the Chief Financial Officer for Hims & Hers Health, Inc., has completed a series of transactions involving the company’s Class A Common Stock. The activity, executed on July 6, 2026, was conducted in accordance with a Rule 10b5-1 trading plan that the executive adopted on May 21, 2025. Under this plan, Mr. Oluyemi exercised stock options and immediately sold the resulting shares.
The transaction involved the sale of 7,163 shares of Class A Common Stock, generating a total value of approximately $261,351. The shares were divested at an average weighted price of $36.4863 per share. Individual sales within this block occurred within a price range spanning from $36.35 to $36.70. Prior to executing the sale, Mr. Oluyemi acquired the 7,163 shares by exercising stock options at a price of $5.01 per share, with the total cost of this acquisition amounting to approximately $35,886.
The stock options exercised were part of a grant structured with specific vesting conditions. According to the terms, 25% of the grant vested on the twelve-month anniversary of January 24, 2022, with the remaining balance vesting in monthly installments contingent upon continuous service. The exercised options carried an expiration date of February 23, 2032. Following these transactions, Mr. Oluyemi directly holds 284,321 shares of Hims & Hers Health, Inc. Class A Common Stock. Additionally, 7,853 shares are held indirectly by the Oluyemi Okupe Separate Property Trust.
This executive activity occurs as Hims & Hers Health navigates a period of analyst optimism and strategic shifts. The telehealth company has seen a series of positive developments, including price target increases from major financial institutions. Barclays raised its price target for Hims & Hers from $29 to $39, maintaining an Overweight rating. This decision was influenced by data showing improved performance following a partnership with Novo Nordisk, with website traffic reporting significant year-over-year increases in April and May.
Canaccord also raised its price target for the company to $40 from $32, maintaining a Buy rating. The firm cited the company’s transition from compounded to branded weight loss drugs and its strong partnership with Novo Nordisk as key factors. Additionally, BofA Securities adjusted its price target to $36 from $25, while keeping a Neutral rating. The adjustment noted the impact of the FDA’s review of wellness peptides, with the agency’s move to review and potentially remove certain peptides from the restricted list potentially opening up a new market for the company.
These analyst updates reflect a positive outlook on Hims & Hers Health’s recent strategic moves and market opportunities. The company’s efforts in the weight loss drug sector and its partnerships have been highlighted as key factors in these assessments. The transaction comes as the stock has gained over 10% in the past week, though analysis suggests the company is currently overvalued relative to its Fair Value. With a market cap of $8.4 billion and revenue growth of 33%, the telehealth company maintains a